Unity Biotechnology, Inc. (0YC0.L)
0YC0.L Stock Price Chart
Explore Unity Biotechnology, Inc. interactive price chart. Choose custom timeframes to analyze 0YC0.L price movements and trends.
0YC0.L Company Profile
Discover essential business fundamentals and corporate details for Unity Biotechnology, Inc. (0YC0.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
4 Oct 2018
Employees
16.00
Website
https://unitybiotechnology.comCEO
Anirvan Ghosh
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
0YC0.L Financial Timeline
Browse a chronological timeline of Unity Biotechnology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 20 Apr 2026
Upcoming earnings on 5 Mar 2026
Upcoming earnings on 3 Nov 2025
Upcoming earnings on 4 Aug 2025
Earnings released on 22 Apr 2025
EPS came in at -$0.43 falling short of the estimated -$0.40 by -8.20%.
Earnings released on 7 Mar 2025
EPS came in at -$0.50 falling short of the estimated -$0.39 by -29.67%.
Earnings released on 5 Nov 2024
EPS came in at -$0.38 surpassing the estimated -$0.40 by +4.69%.
Earnings released on 7 Aug 2024
EPS came in at -$0.31 surpassing the estimated -$0.46 by +32.05%.
Earnings released on 15 May 2024
EPS came in at -$0.34 surpassing the estimated -$0.61 by +43.11%.
Earnings released on 13 Mar 2024
EPS came in at -$0.28 surpassing the estimated -$0.69 by +59.95%.
Earnings released on 14 Nov 2023
EPS came in at -$1.05 falling short of the estimated -$0.86 by -21.99%.
Earnings released on 9 Aug 2023
EPS came in at -$0.85 falling short of the estimated -$0.80 by -5.61%.
Earnings released on 10 May 2023
EPS came in at -$0.76 surpassing the estimated -$1.08 by +29.66%.
Stock split effective on 30 Mar 2023
Shares were split 1:10, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Mar 2023
EPS came in at -$1.00 surpassing the estimated -$1.03 by +2.42%.
Stock split effective on 20 Oct 2022
Shares were split 1:10, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2022
EPS came in at -$1.36 surpassing the estimated -$1.56 by +13.01%.
Earnings released on 30 Jun 2022
EPS came in at -$1.90 surpassing the estimated -$2.63 by +27.93%, while revenue for the quarter reached $236.00K.
Earnings released on 9 May 2022
EPS came in at -$2.80 falling short of the estimated -$2.50 by -12.11%.
Earnings released on 21 Mar 2022
EPS came in at -$1.82 surpassing the estimated -$3.40 by +46.46%, while revenue for the quarter reached $4.78M.
Earnings released on 10 Nov 2021
EPS came in at -$3.25.
Earnings released on 30 Sept 2021
EPS came in at -$2.97.
Earnings released on 31 Mar 2021
EPS came in at -$2.91.
Earnings released on 31 Dec 2020
EPS came in at -$3.68.
Earnings released on 30 Sept 2020
EPS came in at -$5.25.
0YC0.L Stock Performance
Access detailed 0YC0.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.